Stockholders' Equity

9 Months Ended

Sep. 30, 2022

Changes in Stockholders’ Equity (Deficit)

The following tables present certain information regarding our stockholders’ equity (deficit) as of September 30, 2022 and 2021:


	Nine Months Ended September 30, 2022
	Common Stock		Additional Paid in Capital		Retained Earnings (Accumulated Loss)		Treasury Stock		Accumulated Other Comprehensive Loss		Noncontrolling Interest		Total
January 1, 2022	$	1	$	1,337	$	(3,158)	$	(175)	$	(261)	$	150	$	(2,106)
Settlement of liability awards and other, net	—		43		—		—		—		—		43
Vesting of RSUs, net of tax withholdings	—		(31)		—		—		—		—		(31)
Purchase of treasury stock	—		—		—		(51)		—		—		(51)
Stock-based compensation	—		17		—		—		—		—		17
Net income	—		—		26		—		—		2		28
Other comprehensive loss	—		—		—		—		(37)		—		(37)
March 31, 2022	$	1	$	1,366	$	(3,132)	$	(226)	$	(298)	$	152	$	(2,137)
Vesting of RSUs, net of tax withholdings and other	—		—		—		—		—		—		—
Purchase of treasury stock	—		—		—		(152)		—		—		(152)
Purchase of SciPlay common stock	—		(6)		—		—		—		(1)		(7)

Stock-based compensation	—		15		—		—		—		—		15
Net income	—		—		3,291		—		—		4		3,295
Other comprehensive loss(1)	—		—		—		—		(48)		—		(48)
June 30, 2022	$	1	$	1,375	$	159	$	(378)	$	(346)	$	155	$	966
Vesting of RSUs, net of tax withholdings and other	—		(3)		—		—		—		—		(3)
Purchase of SciPlay common stock	—		(10)		—		—		—		(1)		(11)
Stock-based compensation	—		14		—		—		—		—		14
Net income	—		—		328		—		—		7		335
Other comprehensive loss(1)	—		—		—		—		(69)		—		(69)
September 30, 2022	$	1	$	1,376	$	487	$	(378)	$	(415)	$	161	$	1,232

(1) Includes reclassifications of $51 million and $74 million for the three and nine months ended September 30, 2022, respectively, from accumulated other comprehensive loss into income due to the sales of discontinued operations (see Note 2).


	Nine Months Ended September 30, 2021
	Common Stock		Additional Paid in Capital		Accumulated Loss		Treasury Stock		Accumulated Other Comprehensive Loss		Noncontrolling Interest		Total
January 1, 2021	$	1	$	1,268	$	(3,529)	$	(175)	$	(218)	$	129	$	(2,524)
Vesting of RSUs, net of tax withholdings and other	—		(13)		—		—		—		—		(13)
Stock-based compensation	—		17		—		—		—		—		17
Net (loss) income	—		—		(15)		—		—		6		(9)
Other comprehensive income	—		—		—		—		8		—		8

March 31, 2021	$	1	$	1,272	$	(3,544)	$	(175)	$	(210)	$	135	$	(2,521)
Vesting of RSUs, net of tax withholdings and other	—		(4)		—		—		—		—		(4)

Stock-based compensation	—		31		—		—		—		—		31
Net income	—		—		109		—		—		4		113
Other comprehensive income	—		—		—		—		11		—		11
June 30, 2021	$	1	$	1,299	$	(3,435)	$	(175)	$	(199)	$	139	$	(2,370)
Vesting of RSUs, net of tax withholdings and other	—		(3)		—		—		—		—		(3)
Stock-based compensation	—		22		—		—		—		—		22
Net income	—		—		182		—		—		5		187
Other comprehensive loss	—		—		—		—		(27)		—		(27)
September 30, 2021	$	1	$	1,318	$	(3,253)	$	(175)	$	(226)	$	144	$	(2,191)

Stock Based Compensation

The following reflects total stock-based compensation expense recognized under all programs in our continuing operations:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Related to L&W stock options	$	—	$	3	$	1	$	25
Related to L&W RSUs	12		23		39		51
Related to SciPlay RSUs	3		—		7		5
Total	$	15	$	26	$	47	$	81

Restricted Stock Units

A summary of the changes in RSUs outstanding under our equity-based compensation plans during the nine months ended September 30, 2022 is presented below:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value
Unvested RSUs as of December 31, 2021	2.7	$	32.03
Granted	1.7	$	57.26
Vested	(1.9)	$	38.75
Cancelled	(0.7)	$	37.75
Unvested RSUs as of September 30, 2022	1.8	$	46.50

The weighted-average grant date fair value of RSUs granted during the nine months ended September 30, 2022 and 2021 was $57.26 and $55.01, respectively. The fair value of each RSU grant is based on the market value of our common stock at the time of grant. As of September 30, 2022, we had $54 million in total unrecognized stock-based compensation expense

relating to unvested RSUs that will be amortized over a weighted-average period of approximately two years. The fair value at vesting date of RSUs vested during the nine months ended September 30, 2022 and 2021 was $71.6 million and $74.1 million, respectively.

Share Repurchase Programs

As described in Note 17 within our 2021 10-K and in our Current Report on Form 8-K filed with the SEC on March 1, 2022, our Board of Directors approved a share repurchase program under which the Company is authorized to repurchase, from time to time through February 25, 2025, up to an aggregate amount of $750 million of our outstanding common stock. During the nine months ended September 30, 2022, we repurchased 3.7 million shares of common stock under the program at an aggregate cost of $203 million and an average of $55.39 per share. Subsequent to September 30, 2022 and through November 4, 2022, we purchased an additional 0.7 million shares of common stock at an aggregate cost of $38 million.

On May 9, 2022, SciPlay’s Board of Directors approved a share repurchase program under which it is authorized to repurchase, from time to time through May 9, 2024, up to an aggregate amount of $60 million of its outstanding Class A common stock. During the nine months ended September 30, 2022, SciPlay repurchased 1.4 million shares of Class A common stock under the program at an aggregate cost of $18 million and an average of $13.13 per share. Subsequent to September 30, 2022 and through November 4, 2022, SciPlay purchased an additional 0.7 million shares of common stock at an aggregate cost of $10 million.